Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
BRUNO DE BEZERRIL ANDRADE · VANDERBILT UNIVERSITY MEDICAL CENTER · 2022 · $1,177,109 — PROJECT SUMMARY Recent studies from our group have reported a peripheral blood correlate of risk (COR) transcriptional signature that identified individuals with incipient (asymptomatic) TB who progressed to active (symptomatic) TB disease within 12 months. We have also identified human genetic poly…
Thomas R Hawn · UNIVERSITY OF WASHINGTON · 2022 · $176,343 — Despite the discovery of Mycobacterium tuberculosis (Mtb) over 100 years ago and the availability of effective drugs for over 60 years, there remain formidable hurdles for controlling tuberculosis (TB) disease including the lack of a highly efficacious vaccine, long drug treatment regimens, preventi…
ELLIS L REINHERZ · DANA-FARBER CANCER INST · 2022 · $713,250 — ABSTRACT Programming the immune system to detect neoantigens and destroy tumors is critical for effective immunotherapy. Until now, bioinformatic prediction of neoepitopes on tumors from Next Generation Sequencing (NGS) information has been used alone or in conjunction with immunological assays to i…
Paola Massari · TUFTS UNIVERSITY BOSTON · 2022 · $580,195 — Neisseria gonorrhoeae is the causative agent of the sexually transmitted infection (STI) gonorrhea, a disease with high morbidity worldwide, estimated at 87 million cases annually, and severe reproductive tract complications in women. Current treatment approaches against gonorrhea are compromised by…
Siyuan Ding · WASHINGTON UNIVERSITY · 2022 · $393,750 — Project Summary Rotaviruses (RVs) are a medically important human pathogen and the predominant cause of severe gastroenteritis, vomiting, and diarrhea in infants and young children worldwide. RVs are also a great model to interrogate the antiviral responses at the host mucosal surfaces. Our overall…
Amit Kapoor · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · 2022 · $614,828 — Abstract Although direct acting antivirals can cure Hepatitis C virus (HCV) infection, a vaccine is necessary to stop new infections, and to prevent re-infections in the cured individuals. Studies in humans and chimpanzees suggest that both T cells and neutralizing antibodies (nAb) can play an impor…
Jianrong Li · OHIO STATE UNIVERSITY · 2022 · $469,038 — Abstract This application is to renew a grant to study RNA methylation in pneumoviruses. Pneumoviridae is a new virus family, created in 2016 by elevating the paramyxoviral subfamily Pneumovirinae to family status. The Pneumoviridae family includes two medically important pathogens, human respirator…
Barton F. Haynes · DUKE UNIVERSITY · 2022 · $6,183,078 — A key goal of HIV-1 vaccine development is to induce long-lasting broadly neutralizing antibodies (bnAbs) that can inhibit HIV-1 infection. Messenger (m) RNA has emerged as a promising new vaccine modality that can elicit potent immune responses, while avoiding the safety risks and anti-vector immun…
Ranjit Ray · SAINT LOUIS UNIVERSITY · 2022 · $340,875 — Abstract Chronic hepatitis C virus (HCV) infection often causes end stage liver disease. Although current anti-HCV drugs are successful in eliminating viral RNA load, they do not prevent reinfection. In addition, eliminating HCV RNA load does not reduce the risk for progression to end stage liver di…
Daniel Pearce Depledge · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · 2022 · $562,370 — 7. PROJECT SUMMARY / ABSTRACT Chemical modification of mRNA provides a powerful means to dynamically alter gene expression in eukaryotes via epitranscriptomic changes. In particular, methylation of adenosine at the N6 position (m6A) constitutes the most widespread internal base modification to mRNA.…
Scott F Michael · FLORIDA GULF COAST UNIVERSITY · 2022 · $27,344 — PROJECT SUMMERY Most currently available vaccines, especially live and mRNA-based COVID-19 vaccines, are temperature sensi- tive and require stringent cold-chain maintenance, entailing their storage and distribution at recommended tem- peratures from production to administration. This necessity impo…
Alkesh Harihar Jani · VA EASTERN COLORADO HEALTH CARE SYSTEM · 2022 — Bacterial infections are the second leading cause of death in ESRD. The incidence of pneumonia amongst dialysis patients is increasing and leads to a mortality rate that is 14-16-fold greater than pneumonia in the general population. Little is known regarding the immune response to pneumococcal vacc…
Li Wu · UNIVERSITY OF IOWA · 2022 · $231,750 — Abstract The COVID-19 pandemic caused by severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) has resulted in global health and economic crises. To develop effective vaccines and antivirals to prevent and control SARS-CoV-2 or other coronavirus infections, it is critical to understan…
paolo lusso · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2022 · $1,549,551 — The development of an HIV vaccine has been hampered by unprecedented challenges, primarily due to the unique properties of the HIV-1 envelope (Env) trimer, a cleverly engineered entry machinery that features an extraordinary assortment of immune-evasion tactics, including antigenic variation, heavy …
ALAN REIN · DIVISION OF BASIC SCIENCES - NCI · 2022 · $616,301 — There appear to be several different modes of interaction between retroviral proteins and nucleic acids, each with important functional consequences for viral replication. First, an exquisitely specific recognition by the Gag polyprotein (the structural protein of the virus particle) …
Daniel Cesar Douek · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2022 · $2,530,888 — The Genome Analysis Core (TGAC), within the Human Immunology Section, was set up in 2014 to fulfill many of the specialist sequencing needs of the Vaccine Research Center (VRC). Currently, the VRC is designing, producing and testing candidate immunogens aimed at eliciting broadly neutralizing antibo…
NANCY J SULLIVAN · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2022 · $164,928 — In these studies, we are evaluating a vaccine against Monkeypox that utilizes an mRNA platform, which has a more favorable safety profile and scalability. Manufacturing is also scalable with a short lag time from immunogen design to production making it amenable for rapid deployment of new antigens …
Florian Krammer · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2022 · $283,216 — Summary SARS-CoV-2 vaccines have been developed in record time and are now widely used in many different countries around the globe. Project 1 will focus on characterizing immune signatures associated with SARS-CoV-2 immunization using different vaccine types. In Aim 1 we will leverage existing bios…
Annick Desjardins · DUKE UNIVERSITY · 2022 · $564,267 — PROJECT SUMMARY – Project 1 We recently reported in Nature that patients with glioblastoma (GBM) randomized to receive a vaccine against Cytomegalovirus (CMV) major integument protein pp65 using a tetanus/diphtheria (Td) vaccine site preconditioning regimen had a statistically significant increase i…
BRIAN KELSALL · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2022 · $1,795,398 — This project focuses on the roles of different populations of dendritic cells (DC) and macrophages (MP) in immune responses in mucosal tissues. While it is clear that the normal outcome of mucosal antigen exposure can be positive, i.e., the development of intestinal IgA and effector T cell responses…